OXURION NV obtains a convertible bond of 10 million euros
Pprovides additional capital to advance developmentp of the society Innovative novel pipeline Clinical assets, THR-687 and THR-149
Leuven, BE, Boston, Massachusetts, United States – November 22, 2021 – 07.00 A M HEC – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard ophthalmic therapies, with a portfolio of clinical stages in retinal vascular disorders, announces that it has entered into a 10 million euro loan agreement with Kreos Capital and Pontifax Ventures, which will take the form of convertible bonds (the âDebt Financingâ).
Oxurion is focused on building a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two new therapies. The net proceeds from the debt financing will be used to provide working capital to support Oxurion’s strategy to advance the development of its two clinical-stage assets, THR-687 and THR-149 currently in Phase 2 clinical trials. for Diabetic Macular Edema (âDMEâ) (the âClinical Assetsâ).
THR-687 is a highly selective pan-RGD integrin antagonist which is initially being developed as a potential first-line treatment for patients with DME. THR-687 also has the potential to improve treatment outcomes in patients with age-related wet macular degeneration (“wet AMD”) and macular edema after retinal vein occlusion (“RVO”). THR-149 is a potent plasma kallikrein inhibitor in development as a potential new standard of care for the 40-50% of patients with DME who have a suboptimal response to anti-VEGF therapy. Taken together, the clinical assets have the potential to address and grow the market currently served primarily by anti-VEGF therapy (DME, wet AMD and RVO), which is estimated at + $ 12 billion (GlobalData).
Tom Graney, CFA, CCEO and CFO of Oxurion, “The access to capital provided by this facility is designed to increase our financial flexibility as we continue to advance our Clinical Assets in Phase 2 for DME. We are delighted that such ssophisticated and supporting healthcare investors like Kreos and Pontifax have to acknowledgeD the value of our Clinical assets and our programs doing this capital injection.“
Chris Church, Pmain To Kreos Capital city, added “WWe are delighted to partner with Oxurion providing this capital commitment as part of our soil investment strategy–breakthrough innovations in the life sciences. We recognize the great potential of THR-687 and THR-149 and fully endorse Oxurion’s plans for the development of these assets.
mom Karako, partner of Pontifax Ventures, commented “Oxurion is developing a truly innovative pipeline new assets, which are uniquely positioned to disrupt and grow the more than $ 12 billion anti-VEGF market. Pontifax is happy to Support Oxurion with growth capital and be part of its exciting future.”
The secured credit facility with Kreos Capital and Pontifax Ventures amounts to a total of EUR 10 million in the form of convertible bonds, subject to customary closing conditions. The bonds will have a term of 38 months, consisting of at least eight months of interest-only payments, followed by 30 monthly payments of principal and interest. The bonds will bear interest at a rate of 7.95% per annum. The loan agreement provides for a transaction commission of 125,000 EUR and an end-of-loan commission of 350,000 EUR. The bonds will be convertible into new ordinary shares at 140% of the VWAP 30 days from the third trading day immediately preceding the date of the notarial deed relating to the issue of the bonds.
Combined with available liquidity, debt financing is not sufficient to execute the Company’s current business plan for the next 12 months without the Company accessing the additional 22.5 million euros available from the Negma Group. during this period under the existing funding program, which is subject to certain conditions.
For more information, please contact:
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next-generation standard ophthalmic therapies designed to better preserve vision in patients with retinal vascular disorders, including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients. worldwide as well as other conditions including wet age-related macular degeneration (wet AMD) and retinal vein occlusion (RVO).
Oxurion aims to build the leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two new therapies:
- THR-687 is a highly selective pan-RGD integrin antagonist which is initially being developed as a potential first-line treatment for patients with DME. The first positive results of a phase 1 clinical study evaluating THR-687 as a treatment for DME were announced in 2020. Oxurion is currently conducting a phase 2 clinical trial (âINTEGRALâ) evaluating THR-687 in patients with DME. THR-687 also has the potential to improve treatment outcomes for patients with wet AMD and RVO.
- THR-149 is a potent plasma kallikrein inhibitor in development as a potential new standard of care for the 40-50% of patients with DME who have a suboptimal response to anti-VEGF therapy. THR-149 has shown positive Phase 1 results for the treatment of DME. The Company is currently conducting a phase 2 clinical trial (âKALAHARIâ) evaluating multiple injections of THR-149 in patients with DME previously showing a suboptimal response to anti-VEGF treatment. Following the positive data from part A of this phase 2 study (dose selection), the Company is recruiting subjects for part B of the study.
Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels stock exchange under the symbol OXUR. More information is available at www.oxurion.com.
About Kreos Capital
Kreos Capital is the leading provider of growth debt in Europe and Israel, supporting high growth companies at every stage of their lifecycle. Kreos targets investments in all areas of the tech and healthcare sectors and, to date, has committed more than â¬ 3.1 billion in more than 630 portfolio company transactions, in 17 countries. With over $ 1.5 billion in funds under management, Kreos can invest between $ 2.0 million and $ 100.0 million per transaction in public and private companies at all stages.
On Pontifax Enterprises
Founded in 2004, Pontifax is a dedicated healthcare venture capital firm with over $ 1.2 billion under management. It seeks transformative and cutting-edge technologies in life sciences at all stages of development. Its portfolio includes a hundred companies that develop revolutionary solutions for substantial unmet needs.
Important information about forward-looking statements
Certain statements contained in this press release may be considered “forward-looking”. These forward-looking statements are based on current expectations and, therefore, involve and are influenced by various risks and uncertainties. The Company can therefore provide no assurance that these forward-looking statements will materialize and assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or for any other reason. . Additional information regarding the risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s annual report. This press release does not constitute an offer or invitation to sell or purchase any securities or assets of Oxurion in any jurisdiction. No security of Oxurion may be offered or sold in the United States without registration under the US Securities Act of 1933, as amended, or in accordance with an exemption therefrom, and in accordance with state securities laws. applicable Americans.